Title: Sequential Transarterial Chemoembolization and Early Radiofrequency Ablation
Improves Clinical Outcomes for Early-intermediate Hepatocellular Carcinoma in a 10-year
Single-center Comparative Study
Version: 3 Date: 17 Dec 2020
Reviewer's report:
-The manuscript is generally well written.
-The methodology described is sound and the conclusions obtained from the data are
appropriately stated.
-Questions:
*1. (page 5, line 110) What was the tumor size limitation of the patients who were included, it
should be specified in the including criterion.
*2. (page 6, line 115) What was the definition of hemorrhagic risk ? Was it defined by INR or
platelets? should be stated clearly.
*3. (page 6, line 128) “The dosage of lipiodol and doxorubicin hydrochloride was determined
according to the tumor’s size and vascularity, and the patient’s underlying liver function”. How
was the dosage of lipiodol and doxorubicin be determined by liver function? it should better
be quantified.
*4. (page 8, line 162) When was the palliative TACE identified intolerable? Was the palliative
TACE continued to be performed when it failed to control tumor progression? Was other therapy
used after progression?
*5. The 95%CI of median OS (page 10, line 203) and (line 209) median OS should be provided
in the session of Result.
*6. (page 11, line 235) The reasons why some patients failed to receive combination therapy
within two weeks may be specified and discussed.
Title: Sequential Transarterial Chemoembolization and Early Radiofrequency Ablation
Improves Clinical Outcomes for Early-intermediate Hepatocellular Carcinoma in a 10-year
Single-center Comparative Study
Version: 3 Date: 17 Dec 2020
Reviewer's report:
-The manuscript is generally well written.
-The methodology described is sound and the conclusions obtained from the data are
appropriately stated.
-Questions:
*1. (page 5, line 110) What was the tumor size limitation of the patients who were included, it
should be specified in the including criterion.
*2. (page 6, line 115) What was the definition of hemorrhagic risk ? Was it defined by INR or
platelets? should be stated clearly.
*3. (page 6, line 128) “The dosage of lipiodol and doxorubicin hydrochloride was determined
according to the tumor’s size and vascularity, and the patient’s underlying liver function”. How
was the dosage of lipiodol and doxorubicin be determined by liver function? it should better
be quantified.
*4. (page 8, line 162) When was the palliative TACE identified intolerable? Was the palliative
TACE continued to be performed when it failed to control tumor progression? Was other therapy
used after progression?
*5. The 95%CI of median OS (page 10, line 203) and (line 209) median OS should be provided
in the session of Result.
*6. (page 11, line 235) The reasons why some patients failed to receive combination therapy
within two weeks may be specified and discussed.
Please review this paper.
user
Title: Sequential Transarterial Chemoembolization and Early Radiofrequency Ablation
Improves Clinical Outcomes for Early-intermediate Hepatocellular Carcinoma in a 10-year
Single-center Comparative Study
Version: 3 Date: 17 Dec 2020
Reviewer's report:
-The manuscript is generally well written.
-The methodology described is sound and the conclusions obtained from the data are
appropriately stated.
-Questions:
*1. (page 5, line 110) What was the tumor size limitation of the patients who were included, it
should be specified in the including criterion.
*2. (page 6, line 115) What was the definition of hemorrhagic risk ? Was it defined by INR or
platelets? should be stated clearly.
*3. (page 6, line 128) “The dosage of lipiodol and doxorubicin hydrochloride was determined
according to the tumor’s size and vascularity, and the patient’s underlying liver function”. How
was the dosage of lipiodol and doxorubicin be determined by liver function? it should better
be quantified.
*4. (page 8, line 162) When was the palliative TACE identified intolerable? Was the palliative
TACE continued to be performed when it failed to control tumor progression? Was other therapy
used after progression?
*5. The 95%CI of median OS (page 10, line 203) and (line 209) median OS should be provided
in the session of Result.
*6. (page 11, line 235) The reasons why some patients failed to receive combination therapy
within two weeks may be specified and discussed.
assistant